



Zeal & Innovation in **M**edicine

Ref No.: ZLL/CS/BSE/NSE

Date: 03.08.2024

BSE Limited, Corporate Relationship Department P. J. Towers, Dalal Street, Mumbai- 400 001 Company Code- 541400	National Stock Exchange of India Limited Listing Compliance Department Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 (Symbol - ZIMLAB)
---	---

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR'), we wish to inform you that the Board of Directors in their meeting held on 03rd August, 2024 have considered and inter alia approved the following:

1. Investment of upto Euro 1,53,000 in the equity shares of SIA ZIM Laboratories Limited, Wholly owned Subsidiary of the Company.
2. Incorporation of a Subsidiary of ZIM Laboratories FZE, Sharjah (Wholly owned subsidiary of the Company). Post investment, the newly incorporated subsidiary would be a step-down subsidiary of the Company.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1 /P/CI R/2023/123 dated July 13, 2023 are also enclosed as Annexure I & II.

Kindly take the intimation on record.

Thanking you,

Yours faithfully,
For ZIM LABORATORIES LIMITED

(Piyush Nikhade)
Company Secretary and Compliance Officer
Membership No. A38972

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172



Zeal & Innovation in **M**edicine

Disclosure under sub-para (1) [i.e., Acquisition(s) (including agreement to acquire)] of Para (A) of Part (A) of Schedule III to the Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015:

Annexure I

Sr. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	Entity Name: SIA ZIM Laboratories Limited. The Company was incorporated in September, 2019. Turnover: NIL (As the Company is yet to commence the operations)
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length"	Subscription to shares of SIA ZIM Laboratories Limited is not a related party transaction, however, SIA ZIM Laboratories Limited is a wholly owned subsidiary of the Company and is categorised as a Related Party of the Company. Mr. Zulfiqar Kamal, one of the Promoters of the Company is appointed as Directors on the Board of SIA ZIM Laboratories Limited.
3	Industry to which the entity being acquired belongs	Pharmaceuticals
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The investment in equity shares of SIA ZIM Laboratories Limited is with an objective of expansion and development of business in the European region.
5	Brief details of any governmental or regulatory approvals required for the acquisition.	Not Applicable
6	Indicative time period for completion of the acquisition	Not Applicable

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172



Zeal & Innovation in **M**edicine

7	Nature of consideration – whether cash consideration or share swap and details of the same	Cash Consideration
8	Cost of acquisition or the price at which the shares are acquired	Company will invest upto Euro 1,53,000 for acquisition of equity shares of SIA ZIM Laboratories Limited.
9	Percentage of shareholding /control acquired and / or number of shares acquired	With the proposed investment, the Company's shareholding in SIA ZIM Laboratories Limited remains at 100%.
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	SIA ZIM Laboratories Limited was incorporated in Latvia, Europe in September, 2019 to operate in Pharmaceutical Industry and is yet to commence its business operations.

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172

Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur
Maharashtra, India. Ph. + 91.718.271370 | Fax : +091.7118.271470

Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square,
Nagpur – 440013. Maharashtra, India. Ph. +091.712.2981960



Zeal & Innovation in **M**edicine

**Disclosure under sub-para (1) [i.e., Acquisition(s) (including agreement to acquire)]
of Para (A) of Part (A) of Schedule III to the Regulation 30 of SEBI (Listing Obligation
and Disclosure Requirements) Regulations, 2015:**

Annexure II

Sr. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	Entity Name: ZIM Scientific Office L.L.C or any other name as approved by the regulatory authority. Turnover: NIL (As the Company is yet to be incorporated)
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length"	The said transaction is not a related party transaction. Dr. Anwar Daud and Mr. Zulfiqar Kamal, Promoters of the Company are proposed to be appointed as Directors on the Board of ZIM Scientific Office L.L.C or any other name as approved by the regulatory authority (Step down subsidiary of the Company).
3	Industry to which the entity being acquired belongs	Pharmaceuticals
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The incorporation of step down subsidiary is with an objective of expansion and development of business in the MENA region.
5	Brief details of any governmental or regulatory approvals required for the acquisition.	Not Applicable
6	Indicative time period for completion of the acquisition	Not Applicable

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172



Zeal & Innovation in **M**edicine

7	Nature of consideration – whether cash consideration or share swap and details of the same	Cash Consideration
8	Cost of acquisition or the price at which the shares are acquired	ZIM Laboratories FZE (wholly owned subsidiary of the Company) would invest upto AED 1,00,000 in equity shares in ZIM Scientific Office L.L.C or any other name as approved by the regulatory authority (Step down subsidiary of the Company).
9	Percentage of shareholding /control acquired and / or number of shares acquired	After the proposed investment, ZIM Scientific Office L.L.C or any other name as approved by the regulatory authority would be a 100% subsidiary of ZIM Laboratories FZE, Sharjah (wholly owned subsidiary of the Company)
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Not Applicable as the Company is yet to be Incorporated.

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172

Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur
Maharashtra, India. Ph. + 91.718.271370 | Fax : +091.7118.271470

Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square,
Nagpur – 440013. Maharashtra, India. Ph. +091.712.2981960